Internal Medicine, Hematology & Oncology · Staten Island, NY
NPI
1356596779
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
1050 Clove Rd
Staten Island, NY, 10301
Phone (718) 816-6440
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.4M
119,081 services
Medicare patients, 2024
434
Average age 71
Drug cost, 2024
$8.1M
1,749 prescriptions
Company payments, 2025
$96K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Abhirami Vivekanandarajah was code J1439 (injection, ferric carboxymaltose, 1 mg), 50,250 times for 35 patients. In total Abhirami Vivekanandarajah billed 119,081 services in 152 codes, and Medicare paid $1.4M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-09-25.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 50,250 | 35 | $0.84 | $42K |
| 88185 Surgical Pathology Examination | Office | 6,887 | 214 | $21.82 | $150K |
| 36415 Venipuncture Blood Collection | Office | 1,776 | 410 | $8.64 | $15K |
| 85025 Blood Count | Office | 1,727 | 411 | $7.60 | $13K |
| 80053 Clinical Chemistry | Office | 1,218 | 385 | $10.25 | $12K |
| 99214 Office E&M - Established | Office | 999 | 354 | $105.13 | $105K |
| 82784 Immunoassay | Office | 942 | 204 | $8.97 | $8,448 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 940 | 18 | $0.09 | $84.97 |
| 82728 Clinical Chemistry | Office | 863 | 319 | $13.27 | $11K |
| 83550 Clinical Chemistry | Office | 862 | 319 | $8.48 | $7,306 |
| 83540 Clinical Chemistry | Office | 861 | 319 | $6.30 | $5,424 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 678 | 165 | $52.77 | $36K |
| 83521 Immunoassay | Office | 659 | 207 | $16.87 | $11K |
| 83615 Clinical Chemistry | Office | 623 | 293 | $5.92 | $3,688 |
| 84100 Clinical Chemistry | Office | 404 | 213 | $4.62 | $1,865 |
By year: 2022 $1.0M for 127,744 services; 2023 $1.0M for 152,704 services; 2024 $1.4M for 119,081 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88185 Surgical Pathology Examination | 6,887 | 214 | $21.82 | $150K |
| 36415 Venipuncture Blood Collection | 1,776 | 410 | $8.64 | $15K |
| 85025 Blood Count | 1,727 | 411 | $7.60 | $13K |
| 80053 Clinical Chemistry | 1,218 | 385 | $10.25 | $12K |
| 82784 Immunoassay | 942 | 204 | $8.97 | $8,448 |
| 82728 Clinical Chemistry | 863 | 319 | $13.27 | $11K |
| 83550 Clinical Chemistry | 862 | 319 | $8.48 | $7,306 |
| 83540 Clinical Chemistry | 861 | 319 | $6.30 | $5,424 |
| 83521 Immunoassay | 659 | 207 | $16.87 | $11K |
| 83615 Clinical Chemistry | 623 | 293 | $5.92 | $3,688 |
Medicare prescription drug claims, 2024
In 2024, the drug Abhirami Vivekanandarajah prescribed most often to Medicare patients was Aranesp (Darbepoetin Alfa In Polysorbat), with 167 prescriptions and refills. In total Abhirami Vivekanandarajah wrote 1,749 Medicare prescriptions that cost $8.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Aranesp Darbepoetin Alfa In Polysorbat | 167 | 167 | 51 | $599K |
| Akynzeo Fosnetupitant/Palonosetron | 127 | 128 | 23 | $135K |
| Procrit Epoetin Alfa | 118 | 118 | 25 | $233K |
| Prednisone Generic | 89 | 90 | 21 | $506 |
| Abiraterone Acetate Generic | 72 | 73 | 12 | $233K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 70 | 70 | Under 11 | $720K |
| Anastrozole Generic | 53 | 137 | 22 | $947 |
| Imbruvica Ibrutinib | 48 | 48 | Under 11 | $739K |
| Neulasta Onpro Pegfilgrastim | 44 | 44 | Under 11 | $268K |
| Exemestane Generic | 41 | 113 | 15 | $7,980 |
| Lupron Depot Leuprolide Acetate | 40 | 122 | 16 | $218K |
| Azacitidine Generic | 37 | 39 | Under 11 | $106K |
| Acyclovir Generic | 36 | 64 | Under 11 | $439 |
| Venclexta Venetoclax | 33 | 33 | Under 11 | $441K |
| Eliquis Apixaban | 33 | 38 | Under 11 | $19K |
Brand drugs: 1,091 claims; generic drugs: 658 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Abhirami Vivekanandarajah $96K ($96K in general payments such as food, travel and fees) from 11 companies. The largest payer was Takeda Pharmaceuticals U.S.A., Inc. with $53K.
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 35 | $53K |
| Regeneron Healthcare Solutions, Inc. REGN | 14 | $16K |
| Abbvie Inc. ABBV | 10 | $11K |
| Genzyme Corporation SNY | 8 | $5,340 |
| Exelixis Inc. EXEL | 13 | $3,739 |
| Daiichi Sankyo Inc. 4568.T | 3 | $3,040 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $2,025 |
| Janssen Biotech, Inc. JNJ | 1 | $1,500 |
| Array Biopharma Inc PFE | 4 | $81.21 |
| Pfizer Inc. PFE | 1 | $30.65 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.